Choroideremia is an outer retinal degeneration with a characteristic clinical appearance that was first described in the nineteenth century. The disorder begins with reduction of night vision and gradually progresses to blindness by middle age. The appearance of the fundus in sufferers is recognizable by the characteristic pale color caused by the loss of the outer retina, retinal-pigmented epithelium, and choroidal vessels, leading to exposure of the underlying sclera. Choroideremia shows X-linked recessive inheritance and the choroideremia gene (CHM) was one of the first to be identified by positional cloning in 1990. Subsequent identification and characterization of the CHM gene, which encodes Rab escort protein 1 (REP1), has led to better comprehension of the disease and enabled advances in genetic diagnosis. Despite several decades of work to understand the exact pathogenesis, no established treatments currently exist to stop or even slow the progression of retinal degeneration in choroideremia. Encouragingly, several specific molecular and clinical features make choroideremia an ideal candidate for treatment with gene therapy. This work describes the considerations and challenges in the development of a new clinical trial using adeno-associated virus (AAV) encoding the CHM gene. C horoideremia (CHM; OMIM Phenotype MIM number: 303100; ICD10 code H31.2) is an X-linked, recessive, degenerative disease of the retina. In males, the condition is gradually progressive: This begins with reduced night vision in adolescence and develops with a gradual loss of peripheral vision and blindness in middle age (MacDonald et al. 2009 ). In contrast to Leber congenital amaurosis and many other visual cycle disorders, choroideremia is not thought to affect eye formation and early visual development. The retinal pigment epithelium (RPE), retina, and choroid do, however, begin to slowly undergo atrophy at an early age. The name of the disease refers to the clinical appearance of atrophy of the choroid, and the appearance of the fundus in sufferers is normally easily recognizable because of the characteristic pale color resulting from exposure of the underlying white sclera at later stages of the degeneration (Fig. 1) . Male patients generally maintain good visual acuity until the degener-ation encroaches on the fovea, but underlying changes in the retina can be identified in childhood and are associated with significant reductions in parafoveal retinal sensitivity as measured by psychophysical testing (Jacobson et al. 2006b ). Because disease progression is relatively slow and occurs after the period of visual development, patients have largely unaffected vision, particularly in early life. Hence, the majority of patients would likely benefit from successful therapeutic intervention to preserve remaining vision, even at late stages of the disease.
When examined, most carrier females show characteristic pigmentary changes of the fundus but these are generally nonprogressive if the X-inactivation occurs late during development-in other words, if there is an even and fine distribution of affected and unaffected RPE cells. These individuals remain predominantly asymptomatic in early years, but may develop reduced night vision in later years. In contrast, X-inactivation very early during development can result in large areas of retina affected by choroideremia caused by clonal expansion of cells expressing only the defective CHM gene (the "good" copy on the other X chromosome having been silenced). These rare, severe cases can lead to blindness in female carriers (Bonilha et al. 2008) .
Choroideremia is caused by mutations in the CHM gene (OMIM Gene/Locus MIM number: 300390), which is located on the long arm of the X chromosome (Cremers et al. 1990) . CHM encodes Rab escort protein 1 (REP1), which is sometimes also referred to as component A of Rab geranylgeranyl-transferase (Seabra et al. 1992 (Seabra et al. , 1993 ). This protein is expressed ubiquitously and is found in all cell types and tissues throughout the body. Through its action on Rab GTPases, REP1 plays a role in the fundamental cellular processes of intracellular vesicle trafficking and recycling. Despite about two decades of work to understand the role of REP1 deficiency in the pathogenesis of the disease (e.g., Seabra et al. 1992 Seabra et al. , 1993 Seabra et al. , 1995 Larijani et al. 2003; Pylypenko et al. 2003; Tolmachova et al. 2006 Tolmachova et al. , 2010 , no established treatments currently exist to stop or even slow the progression of retinal degeneration in choroideremia.
Nevertheless, in vivo gene augmentation therapy, in which a working and healthy copy of the gene is introduced into the cells within the body that need it, is an appealing strategy for this currently incurable, blinding disease. The slow rate of degeneration means that there is a long therapeutic window in which to replace the gene in ocular cells before they are lost. In addition, virtually all cases reported so far are functionally null mutations and are often predicted to result in the severe truncation or absence of endogenous REP1 protein (van den Hurk et al. 1997 (van den Hurk et al. , 2003 McTaggart et al. 2002; Esposito et al. 2011) . This is useful because the product of the therapeutic gene will not have to compete with a large pool of mutant protein. This would limit latent dominant negative effects and in theory would mean only a small amount of vector-delivered REP1 might be needed to arrest degeneration. Furthermore, recent reports showing that replacement gene therapy can be safely and successfully used to treat the retinal disease (Leber congenital am- aurosis type 2) (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008) , provide encouragement that a similar technique could be applied to choroideremia.
THE HISTORY, PREVALENCE, AND MOLECULAR-GENETIC DIAGNOSIS OF CHOROIDEREMIA Choroideremia was first described in the nineteenth century by the Austrian ophthalmologist Ludwig Mauthner (1872) . Seemingly as a result of the barren appearance of the fundus, Mauthner named the condition "Chorioideremie," which is thought to be a combination of the ancient Greek "erēmia," meaning barren land or desert, as a suffix to the stem word "chorioid" a common alternative spelling of "choroid" (also originally from ancient Greek words for skin-"chorion," and form/type-"eidos") (Myers 2006) . Thus, the disease name means "an area barren of choroid." This entered English usage as choroideremia, but an alternative spelling, choroideraemia, has been used extensively (e.g., Martin 2010). It is unclear if the addition of an "a" comes from a desire to differentiate the first and second vowel sounds in "erē-mia" (which indeed are different Greek letters). Alternatively, it may have been believed that the disease name was derived by adding the prefix "er-" ( possibly from the Latin "ir-" meaning not/negation) to the suffix "aemia" (derived from ancient Greek and in usage in British medicine as referring to the state or condition of the blood), thereby meaning an observation of "no blood in the choroid." Whatever the case, the preferred modern English spelling is Choroideremia, as the "ae" diphthong, seen increasingly as archaic, is being replaced by a simple "e."
Originally, the disease was thought of as a congenital absence of the majority of the choroid, probably caused by a developmental disorder (Mauthner 1872) . In fact, Theodor Leber saw the same case and classified it as one of retinitis pigmentosa with extreme atrophy of the choroid (reported by Wolf 1930) . Although closer to the truth, Leber's analysis seems to have been rejected at the time, and the idea of the disease being caused by a congenital (and largely stationary) absence of the choroid predominated for several decades. After more cases were studied, it became clear that the stationary nature of the disease was questionable and the idea was flatly rejected by Pameyer et al. (1960) who said that choroideremia should be considered as an "abiotrophic process of the 'tapetum nigrum' (a reference to the RPE) with a secondary progressive dystrophy of the choriocapillary layer and outer retinal layers" and were clear that "the hypothesis of a dysplasia of the choroid as a primary cause of the fundus alterations must be rejected." Even though choroideremia is now accepted as being a progressive degenerative disease, the idea that degeneration of the choroid is the primary cause still lingers in some medical definitions (e.g., Myers 2006) . We now know that the name choroideremia, although an apt description of the fundus appearance of atrophy of the choroid at later stages of the disease, does not reflect the etiology of the disease very well. This is an important consideration when developing therapeutic strategies (see below).
Choroideremia has a prevalence of approximately 1:50,000 in people of European descent, with the highest prevalence in northern Finland (Sankila et al. 1992 ). There are thought to be more than 500 affected male patients in the United Kingdom and around 3000 throughout Europe (MacDonald et al. 2009 ). Thus, although relatively rare, a significant patient population exists for this blinding disease, which lacks any major treatment options.
The characteristic appearance of the fundus can be used to first identify choroideremia clinically. A family history consistent with an X-linked recessive disease can help rule out other diseases with a similar appearance (e.g., gyrate atrophy, Oliver-McFarlane syndrome, bifocal chorio-retinal atrophy). Mutations that cause choroideremia invariably lead to a complete absence of the REP1 protein. Because of this, it has been suggested that clinical diagnosis of choroideremia can be confirmed by the absence of REP1 protein in peripheral blood samples in an immunoblot analysis with anti-REP1 antibody (MacDonald et al. 1998 ). However, genetic testing and molecular diagnosis of a pathogenic mutation in the CHM gene should be used to support the clinical diagnosis. It is possible to order routine sequencing of CHM via health service approved diagnostic laboratories in many countries, including the UK, although in some cases a more thorough examination of the genomic DNA or the mRNA must be performed to detect the molecular cause of CHM (Furgoch et al. 2014 ).
THE EXPRESSION AND FUNCTION OF REP1 PROTEIN
In many inherited retinal dystrophies, the protein product of the causative gene directly contributes to a process that is essential for the lightsensitive function of the eye (such as phototransduction in the retina or the visual cycle in the RPE). This is not the case in choroideremia. Instead, the gene product, REP1, is involved in lipid modification of Rab GTPases, members of the Ras superfamily of monomeric G proteins ( Fig. 2) (Seabra et al. 1992 (Seabra et al. , 1995 Pylypenko et al. 2003) . This modification, known as prenylation, involves the covalent attachment of one or more prenyl groups (geranylgeranyl or farnesyl) to carboxy-terminal cysteines of a Rab protein. REP1 binds newly synthesized, unprenylated Rabs and presents them to a catalytic Rab geranylgeranyltransferase (GGTase) subunit for the geranylgeranyl transfer reaction. REP1 also helps escort prenylated Rabs to their specific destination membrane by binding the hydrophobic, insoluble prenyl groups and carrying them through the cytoplasm (Pylypenko et al. 2003) . Rabs themselves have an important function in intracellular vesicle trafficking, for which the addition of a prenyl moiety "lipid anchor" is essential (Seabra et al. 1995) . Thus, in choroideremia, the affected gene plays a role in fundamental cellular processes.
Within the eye, there are a number of processes reliant on Rab protein function. In the photoreceptor, proteins destined for the outer segment, such as rhodopsin, travel from the Golgi apparatus to the connecting cilium via vesicular transport that is regulated by Rab8 and Rab6. In the RPE, intracellular trafficking controls the phagocytosis and degradation of disk A schematic of the cellular function of Rab escort protein (REP1). REP1 binds Rabs (member of the Ras subfamily of small GTPases, 70 members) as they are made by ribosomes (R) on the endoplasmic reticulum (ER). REP1 present newly synthesized, unprenylated Rabs to a catalytic Rab geranylgeranyltransferase (GGTase) subunit. Rabs undergo prenylation, which involves the covalent attachment of one or more hydrophobic prenyl groups (geranylgeranyl, GG shown here) to carboxy-terminal cysteine residues. REP1 also escorts prenylated Rabs to specific destination membranes in the Golgi apparatus (GA) and of diverse cellular vesicles (Vesicle, represents various cellular vesicles, e.g., lysosomes or transport vesicles).
A.R. Barnard et al. membranes shed from the apical tips of photoreceptor outer segments. It is believed that Rab proteins function during phagocytosis by the RPE, possibly through an effector-mediated interaction with myosin VIIA, which is required for phagosome transport (Gibbs et al. 2003) .
Although choroideremia is almost exclusively a disease affecting the eye, REP1 is expressed in all cells and tissues throughout the body. As an additional complexity, mammals (including man) also produce REP2, a protein very similar to REP1, with an (amino acid sequence 75% identical, 90% similar to REP1) . REP2 is encoded by the gene CHML (choroideremia-like), which resides on chromosome 1 and is thought to have arisen from a retrogene insertion of the REP1 mRNA transcript sometime during vertebrate evolution (as evidenced by the lack of introns). REP2, like REP1, is expressed ubiquitously. Thus, loss of REP1 function can in theory be compensated for by the action of REP2, at least in cells outside the eye.
It is thought, therefore, that the phenotype of choroideremia is not so much dictated by the cells in which REP1 is normally expressed, but by those in which REP2 is unable to compensate for its function, for whatever reason. It has been shown that some Rabs, such as Rab27a, are preferentially prenylated by REP1 (Larijani et al. 2003) . Rab27a has a key role in the retina (Tolmachova et al. 1999) , and its affinity toward REP1 and REP2 proteins is similar. However, the Rab27a-REP1 and Rab27a-REP2 complexes have different affinities for the Rab GGTase enzyme, which might explain why REP2 is unable to support Rab27a prenylation in the retina of choroideremia patients over the long term (Larijani et al. 2003) .
INVESTIGATING THE PATHOLOGY OF REP1 DEFICIENCY USING LABORATORY ANIMAL MODELS
To investigate the pathology of choroideremia, researchers have attempted to develop laboratory animal models of the disease. However, the global ablation of CHM gene function appears to be more severe in animal models than in humans. In the zebrafish, a common nonmammalian vertebrate model organism, mutation of the chm gene leading to a completely nonfunctional (null) allele manifests as an extremely severe systemic illness resulting in early lethality at postnatal day 6 (Starr et al. 2004; Moosajee et al. 2009 ). This may be explained by the fact that chml/Rep2 is not present in the zebrafish genome (Moosajee et al. 2009 ). In mice, despite the presence of the Chml gene, the genetic deletion of Chm causes embryonic lethality in hemizygous male mice (Chm null /Y), caused by abnormalities in extraembryonic tissues such as the placenta and yolk sac (Shi et al. 2004 ). Interestingly, carrier female mice (Chm null/þ ) are viable and do show progressive retinal degeneration (van den Hurk et al. 1997; Tolmachova et al. 2006) . Thus, the Chm null/þ female mouse seems to best model the phenotype of affected hemizygous male patients. The reasons for this are not completely clear, but subtle species differences in RabGGT compatibility with REP2-Rab complexes and differences in X-inactivation may partially explain why the sex-linked phenotype of choroideremia differs substantially between species.
An important question in choroideremia pathology has been whether one cell type/tissue layer acts as a primary site of degeneration (which then leads to the demise of the other cell types/tissue layers) or if the disease appears in multiple cell types/tissue layers independently and/or simultaneously. The answer dictates which cell types need to be targeted by for gene replacement therapy (and which can or should be avoided). The question is complicated by the fact that the three affected eye layers (choroid, photoreceptors, and RPE) are highly interdependent. For example, genetically normal photoreceptors will degenerate secondary to loss of the RPE by any cause (for instance, in myopic and dry age-related macular degeneration), and the morphology and distribution of RPE cells will change in response to photoreceptor loss (as in many forms of retinitis pigmentosa, for example).
Therefore, more complex animal models have been used in an attempt to dissect the intricate pathologic changes that occur during the choroideremia degenerative process. Krock et al. www.perspectivesinmedicine.org (2007) used the chm zebrafish model to create genetically mosaic mutant/wild-type eyes (by transplanting cells in blastula stage embryos) and found that REP1 appears to be critical for the pigment epithelium but not photoreceptors. In the mouse, a conditional knockout allele (Chm Flox ) has been made that allows for the selective ablation of the Chm gene in a particular cell/tissue type (Tolmachova et al. 2006) . When Chm was selectively ablated in either the neurosensory retina or the RPE, it was found that different subsets of Rabs were underprenylated, implying that both layers have an intrinsic prenylation defect (Tolmachova et al. 2006) . In further work, Chm was selectively ablated in photoreceptor cells or the RPE, resulting in independent degeneration of both layers (Tolmachova et al. 2010) . Although neither condition could initiate significant degeneration of the other layer, the inherent and cell-autonomous need for REP1 function in the photoreceptors and RPE means that both layers could be considered primary sites of the disease (Tolmachova et al. 2010) . Furthermore, when ablation of Chm in the RPE and photoreceptors was combined in the same mouse line, the phenotype was greater than the sum of the effects observed by ablating Chm in each cell type separately (Tolmachova et al. 2010 ). This highlights once again that the adjacent cell layers in the eye influence each other and that these interactions are important factors that can determine the degenerative process in choroideremia.
Overall, the animal models indicate that REP1 deficiency causes cell-autonomous problems in the eye and that both the RPE and retina/photoreceptors can be considered primary sites of the disease. It is logical therefore to propose that future gene therapy approaches for choroideremia should use viral vectors that target both photoreceptors and RPE.
FURTHER CONSIDERATIONS FOR CHOROIDEREMIA PATHOLOGY BASED ON HUMAN DATA
Caution is needed when extrapolating observations from laboratory models directly to humans, because of potential species differences as mentioned above. It is therefore crucial to use human data wherever possible to identify the retinal layers that are wholly dependent on REP1. This information can come from multiple sources, using a range of techniques.
In human female carriers, skewed X-inactivation across the retinal layers can leave affected clones of photoreceptors against normal pigment epithelial cells, and histological postmortem specimens suggest that photoreceptors degenerate independently of the RPE (Flannery et al. 1990; Syed et al. 2001; Bonilha et al. 2008) . There is also evidence from optical coherence tomography scans of male choroideremia patients that the photoreceptor layer thins in advance of degeneration of the RPE (Jacobson et al. 2006b ).
This data confirm the logic of designing a REP1-expressing vector that targets both the photoreceptor layer and the RPE, but further refinement might also be necessary. Because the early stages of choroideremia manifest as loss of night vision, with central, cone-mediated vision preserved until very late stages of the disease, it seems reasonable to assume that rods are affected significantly more than cones. For reasons that are not completely clear, cones are known to be dependent on surrounding rods, and any genetic condition that causes rod death will also lead to complete loss of cones in a centripetal pattern as a secondary phenomenon. In a postmortem analysis of the retina from an X-linked carrier female, apparently normal-looking, REP1-deficient cones could be identified within regions containing REP1 expressing rods (Syed et al. 2001) . The differential expression of REP1 in these two photoreceptor subclasses results from differential X-inactivation (Reese et al. 1995) and provides further evidence that cones may exist without REP1 when surrounded by rods. It therefore seems reasonable to assume that cone death may occur as a phenomenon secondary to loss of rods and RPE, rather than a dependency on REP1. Hence, from a safety perspective, it might actually be better to avoid transduction of cone cells as much as possible.
It might seem ironic that despite the characteristic and defining atrophy of the choroid in choroideremia, the relative importance of REP1 deficiency in the choroidal layers has not been dealt with comprehensively in the available animal models. Fortunately, human data and observations exist that are more illuminating. Studies from postmortem carrier females show no focal loss or abnormalities of the choroid except underlying areas of severe retinal degeneration (Syed et al. 2001) , which suggests that the choroidal vascular system is not dependent on REP1. Similarly, choroideremia is not known to affect blood vessels elsewhere in the body. It is therefore likely that choroidal atrophy occurs secondary to loss of the overlying RPE. In other retinal conditions, the choroid undergoes progressive atrophy many years after subretinal surgery if the pigment epithelium is damaged, leading to a gradual and focal unmasking of scleral autofluorescence, which is similar to the progression of choroideremia (MacLaren et al. 2005) . Despite this, a slow primary degeneration of the choroid cannot be excluded completely.
CHOOSING A GENE THERAPY VECTOR
For gene replacement therapy to work, the genetic material (DNA/RNA) needs a delivery system (vector), and it is common in clinical trials to use a modified virus to carry the gene into cells. Adeno-associated virus (AAV) is currently a popular vector for clinical trials, particularly for ocular gene therapy, but is it applicable for use in choroideremia?
An important issue is the amount of genetic material that can be placed into each viral particle. This is known as the packaging capacity or limit, and for AAV vectors it is thought to be ,5 kb of single-stranded DNA (Wu et al. 2010) . Although this capacity is considered to be small, and a potential limitation of using AAV, it is more than sufficient to include the full coding sequence of REP1 (at 1.9 kb), while still allowing space for a choice of promoters and other regulatory elements.
Another consideration is whether the viral vector can effectively target and transfer DNA to (transduce) the specific cell types and tissues that need to be treated. There are many different AAV subtypes, each with slightly different DNA sequences and capsid proteins on their outer shell (serotypes). These serotypes have different cellular tropism; they preferentially target specific cell types within a given host species. Many AAV vectors target neurons effectively, but only AAV serotype 2 has been shown to transduce both photoreceptors and the RPE after subretinal injection in nonhuman primates (Bennett et al. 1999; Jacobson et al. 2006a ). AAV2 therefore appears to be a good choice, as rod photoreceptors and RPE cells both need to be targeted for REP1 replacement in choroideremia.
In the photoreceptor layer, AAV2 appears to predominantly target rods rather than cones (Bennett et al. 1999) . This is also beneficial because cone photoreceptors do not intrinsically suffer in the absence of REP1 in choroideremia and therefore, from a safety perspective, it might be better to avoid transduction of cone cells as much as possible. However, avoiding cone transduction completely by using AAV2 cannot be guaranteed in the degenerating retina. For instance, in the absence of rods, viral particles are likely to have greater access to cone cells. There may also be promoter-serotype interactions. AAV5, for example, does not transduce macaque primate cones effectively with the CMV promoter (Lotery et al. 2003 ), but it is effective in cones of the squirrel monkey when using a cone-specific promoter (Mancuso et al. 2007) . It is impossible to precisely predict whether AAV2 will limit photoreceptor gene expression exclusively to rod photoreceptors in any given human retinal degeneration; however, it is probably safe to say that AAV2 will target rods more effectively than cones in humans. The tropism of AAV2 for the deeper vascular layers of the choroid is relatively unexplored in animal models and is therefore hard to predict in humans. It seems unlikely that AAV2 will be able to bypass the combined barriers of the RPE and Bruch's membrane, but any possible transduction and treatment of choroidal layers could only be beneficial. As REP1 is ubiquitously expressed, the unlikely event of a more widespread transduction pattern of the gene therapy virus might not be considered a major cause for concern, even in cells and tissue outside the eye.
AAV2 seems a suitable choice for use in choroideremia gene therapy for reasons beyond those described above. Although it is not currently known to cause disease, AAV naturally infects humans (and some other primate species). Consequently, antibodies against capsid antigens of wildtype AAVs can be detected in a significant percentage of humans (Mingozzi et al. 2007) . Despite this, there are extensive safety data in primates (Jacobson et al. 2006a ) and from recent RPE65 gene therapy trials for (LCA2) (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008 ) that show subretinal administration of AAV2 does not cause significant immunogenicity, inflammation, or toxicity. In addition, data from dog models of LCA2 treated with AAV2.RPE65 show that the treated dogs maintain vision without reduction for several years, and even over a decade in some cases Cideciyan et al. 2013) . In humans, clinical trials have shown that visual gains following gene transfer using AAV2.RPE65 are sustained vision for at least 3 yr (Jacobson et al. 2012; Cideciyan et al. 2013; Testa et al. 2013) . Clearly, the lifelong effects in humans will not be known for some time, but these data suggest that expression from the AAV2 vector is sustained, and early loss of therapeutic transgene expression through gene silencing, such as by methylation of the promoter DNA, is not a significant issue. It should be noted, however, that follow-up results from one study (Bainbridge et al. 2008) were never published and, although a maze navigation test in the one reported patient looked impressive, close inspection of the data shows that a similarly dramatic improvement in maze navigation time was seen in the control eye as well. Because RPE65 patients dark-adapt with great difficulty, variation in pretest dark adaptation is a possible explanation for the alleged improvement in vision, as this would also benefit the control eye. In any case, the absence of any follow-up data or further analysis of visual function in this patient raises the possibility that the reported improvement in vision may have been an artifact of testing. It is also unclear why, after 5 yr, there are no reported results for the other nine patients who underwent gene therapy in this trial. The results may have been unspectacular, perhaps owing to the choice of an unsuitable promoter (MacLaren 2009).
Taken together, AAV2 displays tropism for the correct cell types needed, is capable of packaging the full REP1 coding sequence and has been shown to be safe and effective in ocular gene therapy trials for a different eye disease (LCA2) up to 3 yr after treatment. For these reasons, AAV2 was selected for use in a CHM-replacement gene therapy strategy for choroideremia. As AAV2 is such a compelling choice, other types of virus, such as lentiviruses and adenoviruses, were not considered.
DESIGNING AN EFFICIENT AAV2-REP1 EXPRESSION CASSETTE
Because REP1 is ubiquitously expressed, there was little point in using its 5 0 upstream promoter sequence to drive regulated transgene expression. Instead, a well-characterized ubiquitous promoter, capable of driving sustained, high levels of expression, was chosen: a hybrid of the human cytomegalovirus (CMV) upstream enhancer with the chicken b-actin promoter. This promoter, variously termed CBA or CAG, has been used extensively in preclinical studies. The original CBA promoter construct was generated in Japan (Miyazaki et al. 1989; Niwa et al. 1991 ) and first used successfully in AAV in vivo by Mark Sands in the USA (Daly et al. 1999) . A later study showed that an AAV vector with the CBA promoter administered via portal vein injection yielded 9.5-fold higher expression compared to an AAV vector with the EF1a promoter and 137-fold higher expression compared to an AAV vector with the CMV promoter/enhancer, and the CBA-mediated expression was sustained for at least a year (Xu et al. 2001) . CBA promoters have provided highly effective transduction in retinal gene therapy clinical trials (Hauswirth et al. 2008; Maguire et al. 2008 ) and appear to sustain expression for over a decade in dogs Cideciyan et al. 2013 ) and at least 3 yr in humans (Jacobson et al. 2012; Cideciyan et al. 2013; Testa et al. 2013 ).
Other sequences in the transgene expression cassette can be used to improve expression of the therapeutic gene. The inclusion of a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) downstream from the gene coding sequence enhanced AAV transgene expression in the rat brain (Paterna et al. 2000; Klein et al. 2002) , in human embryonic kidney cells (HEK293), and human skin fibroblasts in vitro by up to 10-fold (Loeb et al. 1999 ). Although such an element has not been used previously in retinal gene therapy trials, the same WPRE sequence was approved by the United States Food and Drug Administration and, when used in the AAV2-GAD vector for gene therapy of Parkinson's disease, did not lead to any severe adverse events (Kaplitt et al. 2007 ). Importantly, this WPRE has been modified to ablate the translation initiation site of the viral X antigen, expression of which has previously been linked to increased tumor susceptibility in the liver of mice (Flajolet et al. 1998 ). The choice of polyadenylation signal sequence type can also be used to enhance gene expression. Bovine growth hormone polyA sequence has been shown to yield threefold higher expression levels than do other polyA sequences such as SV40 and human collagen polyA, and this increased expression is largely independent of the type of upstream promoter or transgene (Pfarr et al. 1986 ).
Thus, AAV transgene expression levels can be maximized by a combination of an optimized promoter and polyA signal, along with the inclusion of the WPRE sequence. This allows a lower overall dose of AAV vector to achieve the same therapeutic effect, which is likely to help minimize the immune response to viral proteins in patients. One might argue that this could also be achieved by using other AAV serotypes, such as AAV8, that appear to produce more efficient expression, especially in photoreceptors (Lebherz et al. 2008) . However, as long-term data on safety and sustained expression are currently only available for AAV2, it is preferential to optimize the expression cassette rather than switch capsids.
AAVexpression cassettes must be flanked by identical inverted terminal repeat sequences. These are part of the genome of wild-type AAV and are important in packaging the singlestranded DNA into virions and also in somehow protecting and maintaining the unpackaged DNA in an episomal state in transduced cells. Most inverted terminal repeat sequences used for clinical trials are derived from the genome of AAV2, regardless of which capsid serotype they are packaged into. The full annotation AAV2/2 is used to indicate that AAV2 ITRs have been used to package the expression cassette into the AAV2 serotype.
The final necessary component of the cassette is, of course, the cDNA sequence encoding human REP1. Fortunately, this has previously been fully cloned and characterized (Cremers et al. 1990; van Bokhoven et al. 1994) . Overall, each AAV virion would contain a single stranded DNA sequence of 4.2 kb in length comprising a CMV enhancer/CBA hybrid promoter, human REP1 cDNA, WPRE, and bovine growth hormone polyadenylation sequence (BGH-polyA). This would all be flanked by inverted terminal repeat sequences from the wildtype AAV2 genome. The structural organization of the AAV-REP1 vector is shown in Fig. 3 .
PRECLINICAL TESTING OF THE VECTOR
To translate seamlessly and safely from the laboratory to a clinical trial, the AAV2 expression cassette was produced using protocols that had previously been scaled up to good manufacturing practice grade, approved by the United States Food and Drug Association and used safely in patients in another trial (Kaplitt et al. 2007 ). All preclinical work was conducted using AAV2-REP1 that had been packaged and purified to a research grade standard, but was otherwise identical to the good manufacturing practice-grade vector that could be used in a choroideremia clinical trial (Tolmachova et al. 2013) .
Preclinical testing of the gene therapy expression cassette also involved creation of a green fluorescent protein (GFP) reporter vector. In the reporter vector, the coding sequence of GFP replaced the REP1/Chm cDNA, but otherwise, the structure and sequence were identical.
Subretinal injection of AAV2-GFP reporter vector in mice confirmed targeting of the transgene to RPE and a high level of expression in photoreceptors (Tolmachova et al. 2013) . Furthermore, in vitro treatment of explants of human retina in culture with the AAV2-GFP vector confirmed that the gene therapy expression cassette and capsid type were capable of transducing photoreceptors and driving a high level of transgene expression (Tolmachova et al. 2013) .
Importantly, the AAV2-REP1 vector was able to produce therapeutic protein in cultured fibroblasts of choroideremia patients. By examining prenylation activity in these transduced cells, correct function of the REP1 transgene product could be confirmed (Tolmachova et al. 2013) . Subretinal injection of AAV2-REP1 in wild type mice did not significantly impair retinal function (as assessed by electroretinography), and thus no obvious toxic effects are evident following overexpression of REP1 (Tolmachova et al. 2013) . When subretinal injection of AAV2-REP1 was used to treat Chm null/þ mice, a dose dependent improvement/preservation of retinal function was observed after several months in treated eyes compared to paired, sham-injected control eyes (Tolmachova et al. 2013) . Although large animal models have been used in the preclinical assessment of gene therapy for retinal disease such as LCA2 Cideciyan et al. 2013 ) and achromatopsia (Komaromy et al. 2010) , no such large animal model exists for choroideremia. Thus, using a range of techniques and experiments, preclinical work confirmed the effectiveness and safety of the AAV2-REP1 gene therapy vector.
THE INITIATION OF A GENE THERAPY CLINICAL TRIAL FOR CHOROIDEREMIA
The necessary funding and regulatory and ethical approvals were obtained to embark on a gene therapy trial for choroideremia (ClinicalTrials.gov Identifier: NCT01461213). After a period of enrolment and baseline testing, the first treatment was given in October 2011. In all, the clinical trial will assess the effects of the AAV2.REP1 vector in 12 male patients with a clinical phenotype of choroideremia and a confirmed molecular diagnosis of a null mutation in the gene encoding REP1.
Choroideremia presents a number of challenges for gene therapy. Treatment must be performed when retinal structure relatively intact (i.e., before major cell loss) and when "good" foveal vision is still retained. The potential risks are significant, as delivery of the vector involves detachment of the fovea in a patient with good visual acuity, although if no form of treatment is given, vision will eventually be lost because of the ongoing degeneration. Although there is no preclinical evidence that REP1 is toxic, and it is present in virtually all nucleated cells in nonchoroideremia patients, it is possible that REP1 (over)expression might have a detrimental effect on retinal cells, in particular functional photoreceptors. In addition, this is the first gene Figure 3 . Design of the AAV2/2-REP1 vector used for choroideremia gene therapy. ITR, AAV2 inverted terminal repeats; CMV, cytomegalovirus enhancer element; CBA, chicken b actin promoter; Exon1, chicken b-actin exon 1; Intron, hybrid chicken b-actin and rabbit b-globin intron; Exon2, rabbit b-globin exon 3 fragment (creates an artificial splice site) and human REP1 cDNA (REP1) containing Kozak consensus sequence and start codon initiating translation (Kozak/start) and stop codon terminating translation (stop); WPRE Ã , modified woodchuck hepatitis virus posttranscriptional regulatory element; bGH pA, bovine growth hormone polyadenylation signal.
A.R. Barnard et al. therapy trial for retinal degeneration that specifically targets photoreceptor cells (in trials for RPE65-LCA2, the RPE cells were the primary target).
To ensure that photoreceptor cells are not compromised, the trial involves an escalation of the vector dose from a low baseline level. The starting dose of AAV2 (10 10 genome particles) is at the lower end of the range (10 10 -10 12 ) that has been shown to be safe in current AAV2 ocular gene therapy trials (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008) . Because of this, reactions to AAV capsid protein are unlikely, even allowing for a large number of empty vector particles. The low initial dose also addresses the concern that, because the REP1 protein will be expressed against a null background, there is a theoretical risk of immune reaction to a new protein. The starting dose will be used in the first group of six patients and, if no serious adverse effects or reactions are seen, this will then be increased to a dose of AAV2 that is 10-fold higher (10 11 genome particles) in the second group of six patients.
The primary objective of the study is to assess the safety and tolerability of the AAV2-REP1 vector. This will be performed by monitoring for evidence of ocular inflammation or detrimental effects to visual function in patients for 24 mo after administration. Changes in the treated eye can be compared to baseline measurements and to the fellow untreated eye. Gene transfer to the photoreceptors and RPE cells might enable the cells to survive long-term. The secondary endpoint of the study is to identify any therapeutic benefit of subretinal injection of AAV2-REP1 vector. As choroideremia is a progressive disease, this would be evidenced by a decrease in both loss of visual function and retinal degeneration in the treated eye compared to the control eye at 24 mo after gene delivery. Ophthalmological tests used to assess this will include microperimetry, optical coherence tomography scans and fundus autofluorescence imaging.
Although it is not expected that any anatomical parameter will show an improvement posttreatment compared to baseline, it is possible that there will be some recovery and restoration of vision when measured by the functional tests. These gains might be detected by microperimetry testing. Although male patients generally maintain good visual acuity until the degeneration encroaches on the fovea, significant deficits in parafoveal retinal sensitivity can be seen in more-discriminating tests (Jacobson et al. 2006b) .
If the primary and secondary objectives are met, follow-up clinical trials will be initiated using the same vector at the efficacious dose. Beyond the 24 mo of formal testing, patients will continue long-term follow-up, with further assessments taking place annually as part of normal National Health Service care. This will continue for the lifetime of the patient, and the data will continue to be analyzed by members of the study group to determine if AAV2 transduction of the human retina can result in lifelong gene expression.
CONCLUDING REMARKS
More than 130 yr since the first description of choroideremia, a clinical trial involving gene therapy to treat the disease has begun. The conception and design of the clinical trial has been built on several decades of research focusing on the causes and pathology of the disease. Recent advances in the use of viral vectors for ocular gene therapy have also been invaluable. The trial is the first time photoreceptors have been specifically targeted for treatment in retinal degeneration. It is also the first time treatment of nondegenerated foveas with normal visual acuity has been attempted. Preclinical data on the testing of the AAV2-REP1 gene therapy vector have been encouraging, and the results of the human trial are awaited with great anticipation (MacLaren et al. 2014) 
